Latuda (lurasidone) is a small molecule pharmaceutical. Lurasidone was first approved as Latuda on 2010-10-28. It is used to treat bipolar disorder, major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. The pharmaceutical is active against 5-hydroxytryptamine receptor 7. In addition, it is known to target alpha-2C adrenergic receptor, alpha-2A adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 1A. Latuda's patents are valid until 2031-05-23 (FDA).
|Indication||bipolar disorder, major depressive disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders|
|Drug Class||Antipsychotic with binding activity on serotonin (5HT2A) and dopamine (D2) receptors|